297 related articles for article (PubMed ID: 23440247)
1. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
[TBL] [Abstract][Full Text] [Related]
2. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
6. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
O'Byrne PM; Bleecker ER; Bateman ED; Busse WW; Woodcock A; Forth R; Toler WT; Jacques L; Lötvall J
Eur Respir J; 2014 Mar; 43(3):773-82. PubMed ID: 24136330
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
8. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
[TBL] [Abstract][Full Text] [Related]
9. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
[TBL] [Abstract][Full Text] [Related]
11. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.
Martin N; Weiler JM; Pearlman D; Jacques L; Nunn C; Forth R; West S; Dunn K; O'Byrne PM
J Asthma; 2020 Apr; 57(4):431-440. PubMed ID: 30795705
[No Abstract] [Full Text] [Related]
13. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study.
Jacques L; Bakerly ND; New JP; Svedsater H; Lay-Flurrie J; Leather DA
J Asthma; 2019 Jul; 56(7):748-757. PubMed ID: 29972089
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
17. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials.
Gross AS; Goldfrad C; Hozawa S; James MH; Clifton CS; Sugiyama Y; Jacques L
BMC Pulm Med; 2015 Dec; 15():165. PubMed ID: 26704701
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
Woodcock A; Bleecker ER; Lötvall J; O'Byrne PM; Bateman ED; Medley H; Ellsworth A; Jacques L; Busse WW
Chest; 2013 Oct; 144(4):1222-1229. PubMed ID: 23846316
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
